EGFR and non-small cell lung carcinoma: An analysis of data from Phase III of the FLAURA trial7 comparing osimertinib and gefitinib/erlotinib in patients with common EGFR‐mutated unresectable advanced or metastatic NSCLC demonstrated that osimertinib had superior efficacy in NSCLC in patients with ex19del compared to those with L858R.8